<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39312669</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>40</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>A sensitive assay for measuring whole-blood responses to type I IFNs.</ArticleTitle><Pagination><StartPage>e2402983121</StartPage><MedlinePgn>e2402983121</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e2402983121</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2402983121</ELocationID><Abstract><AbstractText>Human inborn errors of the type I IFN response pathway and auto-Abs neutralizing IFN-α, -β, and/or -ω can underlie severe viral illnesses. We report a simple assay for the detection of both types of condition. We stimulate whole blood from healthy individuals and patients with either inborn errors of type I IFN immunity or auto-Abs against type I IFNs with glycosylated human IFN-α2, -β, or -ω. As controls, we add a monoclonal antibody (mAb) blocking the type I IFN receptors and stimulated blood with IFN-γ (type II IFN). Of the molecules we test, IP-10 (encoded by the interferon-stimulated gene (ISG) <i>CXCL10</i>) is the molecule most strongly induced by type I and type II IFNs in the whole blood of healthy donors in an ELISA-like assay. In patients with inherited IFNAR1, IFNAR2, TYK2, or IRF9 deficiency, IP-10 is induced only by IFN-γ, whereas, in those with auto-Abs neutralizing specific type I IFNs, IP-10 is also induced by the type I IFNs not neutralized by the auto-Abs. The measurement of type I and type II IFN-dependent IP-10 induction therefore constitutes a simple procedure for detecting rare inborn errors of the type I IFN response pathway and more common auto-Abs neutralizing type I IFNs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gervais</LastName><ForeName>Adrian</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Floc'h</LastName><ForeName>Corentin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Voyer</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Immunology Department, Assistance Publique Hôpitaux de Paris, Saint-Louis Hospital, Paris 75010, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bizien</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohlen</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0458-9484</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Celmeli</LastName><ForeName>Fatih</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-2983-5058</Identifier><AffiliationInfo><Affiliation>Division of Pediatric Allergy and Immunology, Antalya Education and Research Hospital, University of Medical Science, Antalya 07100, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Qureshah</LastName><ForeName>Fahd</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5022-9917</Identifier><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masson</LastName><ForeName>Cécile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bioinformatics Core Facility, Université Paris Cité-Structure Fédérative de Recherche Necker, INSERM US24/CNRS UMS3633, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosain</LastName><ForeName>Jérémie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chbihi</LastName><ForeName>Marwa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lévy</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castagnoli</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Pediatric Unit, Department of Clinical, Surgical, Diagnostic, and Pediatric Sciences, University of Pavia, Pavia 27100, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Clinic, Fondazione Istituto di ricovero e cura a carattere scientifico (IRCCS) Policlinico San Matteo, Pavia 27100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothenbuhler</LastName><ForeName>Anya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Endocrinology and Diabetes for children, Reference Center for rare diseases of calcium and phosphate metabolism, OSCAR network, Platform of expertise for rare diseases of Paris Saclay Hospital, Bicêtre Paris Saclay Hospital, Le Kremlin-Bicêtre 94270, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouanguy</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0002-9040-3289</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shen-Ying</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Béziat</LastName><ForeName>Vivien</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4020-824X</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Jacinta</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3439-2482</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Study Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Puel</LastName><ForeName>Anne</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2603-0323</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bastard</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-5926-8437</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Hematology-Immunology and Rheumatology Unit, Necker Hospital for Sick Children, Assistance Publique-Hôpitaux de Paris, Paris 75015, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Casanova</LastName><ForeName>Jean-Laurent</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0002-7782-4169</Identifier><AffiliationInfo><Affiliation>Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Paris Cité University, Imagine Institute, Paris 75015, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>HHMI, New York, NY 10065.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Necker Hospital for Sick Children, Paris 75015, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ANR-22-CE92-0004</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>JPB Foundation (JPBF)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Fondation Bettencourt Schueller (Bettencourt Schueller Foundation)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Meyer Foundation</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>King Abdullah University of Science and Technology (KAUST)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Fondation du Souffle (FdS)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>General Atlantic Foundation</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Battersea &amp;amp; Bowery Advisory Group</Agency><Country /></Grant><Grant><GrantID>ANR-10-LABX-62-IBEID</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>R01 AI127564</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ANR-21-RHUS-08</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>MESRI-COVID-19</GrantID><Agency>French Ministry of Higher Education, Research, and Innovation</Agency><Country /></Grant><Grant><GrantID>ANR-21-LIBA-0002</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Grandir - Fonds de solidarit&amp;amp;#x00E9; pour l&amp;apos;enfance</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Fisher Center for Alzheimer's Research Foundation (Fisher Center)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Stavros Niarchos Foundation (SNF)</Agency><Country /></Grant><Grant><GrantID>R01AI163029</GrantID><Agency>HHS | National Institutes of Health (NIH)</Agency><Country /></Grant><Grant><GrantID>R01 AI095983</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR001866</GrantID><Agency>HHS | NIH | National Center for Advancing Translational Sciences (NCATS)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>King Abdulaziz City for Science and Technology (KACST)</Agency><Country /></Grant><Grant><GrantID>EA20 170638020</GrantID><Agency>Fondation pour la Recherche Médicale (FRM)</Agency><Country /></Grant><Grant><GrantID>ANR-22-CE15-0046</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>01057100 (UNDINE)</GrantID><Agency>EC | HORIZON EUROPE Framework Programme (Horizon Europe)</Agency><Country /></Grant><Grant><GrantID>UL1 TR001866</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>EA20170638020</GrantID><Agency>Fondation pour la Recherche Médicale (FRM)</Agency><Country /></Grant><Grant><GrantID>ANR-20-CE93-003</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>ANR-10-IAHU-01</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>Assistance Publique Hopitaux de Paris</Agency><Country /></Grant><Grant><GrantID>R01AI127564</GrantID><Agency>HHS | National Institutes of Health (NIH)</Agency><Country /></Grant><Grant><GrantID>ANR - 10 - LABX - 62 - 01</GrantID><Agency>Agence Nationale de la Recherche (ANR)</Agency><Country /></Grant><Grant><GrantID>R01 AI163029</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N/A</GrantID><Agency>Square Foundation</Agency><Country /></Grant><Grant><GrantID>N/A</GrantID><Agency>SCOR Corporate Foundation for Science (SCOR Foundation)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054357">Chemokine CXCL10</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114753">CXCL10 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>156986-95-7</RegistryNumber><NameOfSubstance UI="D053633">Receptor, Interferon alpha-beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054357" MajorTopicYN="Y">Chemokine CXCL10</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053633" MajorTopicYN="N">Receptor, Interferon alpha-beta</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">IP-10</Keyword><Keyword MajorTopicYN="N">auto-antibodies</Keyword><Keyword MajorTopicYN="N">diagnostic test</Keyword><Keyword MajorTopicYN="N">type I interferons</Keyword></KeywordList><CoiStatement>Competing interests statement:J.L.-C. is an inventor on patent application PCT/US2021/042741, filed July 22, 2021, submitted by The Rockefeller University and covering the diagnosis of susceptibility to, and the treatment of, viral disease, and viral vaccines, including COVID-19 and vaccine-associated diseases. Reviewer S.R.O. is a co-author of two recent papers with J.L.C. Reviewer P.H. has a collaboration with the Casanova group in the exchange of reagents, but it does not cover the topic of this collaboration.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>18</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>22</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39312669</ArticleId><ArticleId IdType="pmc">PMC11459193</ArticleId><ArticleId IdType="doi">10.1073/pnas.2402983121</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pozzetto B., Mogensen K. E., Tovey M. G., Gresser I., Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J. Infect Dis. 150, 707–713 (1984), 10.1093/infdis/150.5.707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/150.5.707</ArticleId><ArticleId IdType="pubmed">6238105</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogensen K. E., Daubas P. H., Gresser I., Sereni D., Varet B., Patient with circulating antibodies to α-interferon. Lancet 318, 1227–1228 (1981), 10.1016/S0140-6736(81)91460-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(81)91460-4</ArticleId><ArticleId IdType="pubmed">6171694</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J.-L., Ion gresser. J. Interferon Cytokine Res. 39, 317–320 (2019), 10.1089/jir.2018.29015.mem.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2018.29015.mem</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin M., Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e292 (2006), 10.1371/journal.pmed.0030292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030292</ArticleId><ArticleId IdType="pmc">PMC1475656</ArticleId><ArticleId IdType="pubmed">16756392</ArticleId></ArticleIdList></Reference><Reference><Citation>Meager A., et al. , Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006), 10.1371/journal.pmed.0030289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0030289</ArticleId><ArticleId IdType="pmc">PMC1475653</ArticleId><ArticleId IdType="pubmed">16784312</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer S., et al. , AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies. Cell 166, 582–595 (2016), 10.1016/j.cell.2016.06.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.06.024</ArticleId><ArticleId IdType="pmc">PMC4967814</ArticleId><ArticleId IdType="pubmed">27426947</ArticleId></ArticleIdList></Reference><Reference><Citation>Oftedal B. E., et al. , Dominant mutations in the autoimmune regulator AIRE are associated with common organ-specific autoimmune diseases. Immunity 42, 1185–1196 (2015), 10.1016/j.immuni.2015.04.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.04.021</ArticleId><ArticleId IdType="pubmed">26084028</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter J. E., et al. , Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J. Clin. Invest. 125, 4135–4148 (2015), 10.1172/JCI80477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80477</ArticleId><ArticleId IdType="pmc">PMC4639965</ArticleId><ArticleId IdType="pubmed">26457731</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg J. M., et al. , Neutralizing anti-cytokine autoantibodies against interferon-alpha in immunodysregulation polyendocrinopathy enteropathy X-Linked. Front. Immunol. 9, 544 (2018), 10.3389/fimmu.2018.00544.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00544</ArticleId><ArticleId IdType="pmc">PMC5885158</ArticleId><ArticleId IdType="pubmed">29651287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020), 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosain J., et al. , Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases. J. Exp. Med., in press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11448874</ArticleId><ArticleId IdType="pubmed">39352576</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuetz C., et al. , Hypomorphic RAG deficiency: Impact of disease burden on survival and thymic recovery argues for early diagnosis and HSCT. Blood 141, 713–724 (2023), 10.1182/blood.2022017667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2022017667</ArticleId><ArticleId IdType="pmc">PMC10082356</ArticleId><ArticleId IdType="pubmed">36279417</ArticleId></ArticleIdList></Reference><Reference><Citation>De Ravin S. S., et al. , Hypomorphic RAG mutations can cause destructive midline granulomatous disease. Blood 116, 1263–1271 (2010), 10.1182/blood-2010-02-267583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-02-267583</ArticleId><ArticleId IdType="pmc">PMC2938237</ArticleId><ArticleId IdType="pubmed">20489056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosticardo M., Pala F., Notarangelo L. D., RAG deficiencies: Recent advances in disease pathogenesis and novel therapeutic approaches. Eur. J. Immunol. 51, 1028–1038 (2021), 10.1002/eji.202048880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202048880</ArticleId><ArticleId IdType="pmc">PMC8325549</ArticleId><ArticleId IdType="pubmed">33682138</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Voyer T., et al. , Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency. Nature 623, 803–813 (2023), 10.1038/s41586-023-06717-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06717-x</ArticleId><ArticleId IdType="pmc">PMC10665196</ArticleId><ArticleId IdType="pubmed">37938781</ArticleId></ArticleIdList></Reference><Reference><Citation>Oftedal B. E., et al. , A partial form of AIRE deficiency underlies a mild form of autoimmune polyendocrine syndrome type 1. J. Clin. Invest. 133, e169704 (2023), 10.1172/JCI169704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI169704</ArticleId><ArticleId IdType="pmc">PMC10617782</ArticleId><ArticleId IdType="pubmed">37909333</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjøgren T., et al. , Screening patients with autoimmune endocrine disorders for cytokine autoantibodies reveals monogenic immune deficiencies. J. Autoimmun. 133, 102917 (2022), 10.1016/j.jaut.2022.102917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102917</ArticleId><ArticleId IdType="pubmed">36191466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetemaki I., et al. , Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells. Sci. Immunol. 6, eabe3454 (2021), 10.1126/sciimmunol.abe3454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe3454</ArticleId><ArticleId IdType="pubmed">34826260</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Rivero I., et al. , Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. J. Autoimmun. 23, 63–73 (2004), 10.1016/j.jaut.2004.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2004.03.013</ArticleId><ArticleId IdType="pubmed">15236754</ArticleId></ArticleIdList></Reference><Reference><Citation>Meager A., et al. , Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132, 128–136 (2003), 10.1046/j.1365-2249.2003.02113.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2249.2003.02113.x</ArticleId><ArticleId IdType="pmc">PMC1808678</ArticleId><ArticleId IdType="pubmed">12653847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford H. F., et al. , Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNalpha and B cell subsets. Cell Rep. Med. 4, 100894 (2023), 10.1016/j.xcrm.2022.100894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100894</ArticleId><ArticleId IdType="pmc">PMC9873953</ArticleId><ArticleId IdType="pubmed">36652906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S., et al. , Distinct functions of autoantibodies against interferon in systemic lupus erythematosus: A comprehensive analysis of anticytokine autoantibodies in common rheumatic diseases. Arthritis Rheumatol. 68, 1677–1687 (2016), 10.1002/art.39607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39607</ArticleId><ArticleId IdType="pmc">PMC5391258</ArticleId><ArticleId IdType="pubmed">26815287</ArticleId></ArticleIdList></Reference><Reference><Citation>Panem S., Check I. J., Henriksen D., Vilcek J., Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129, 1–3 (1982), 10.4049/jimmunol.129.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.129.1.1</ArticleId><ArticleId IdType="pubmed">6177744</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallbracht A., Treuner J., Flehmig B., Joester K. E., Niethammer D., Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289, 496–497 (1981), 10.1038/289496a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/289496a0</ArticleId><ArticleId IdType="pubmed">6162104</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudick R. A., et al. , Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50, 1266–1272 (1998), 10.1212/wnl.50.5.1266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.50.5.1266</ArticleId><ArticleId IdType="pubmed">9595973</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021), 10.1126/sciimmunol.abl4340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>Puel A., Bastard P., Bustamante J., Casanova J. L., Human autoantibodies underlying infectious diseases. J. Exp. Med. 219, e20211387 (2022), 10.1084/jem.20211387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211387</ArticleId><ArticleId IdType="pmc">PMC8952682</ArticleId><ArticleId IdType="pubmed">35319722</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J. L., Anderson M. S., Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs. J. Clin. Invest. 133, e166283 (2023), 10.1172/JCI166283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI166283</ArticleId><ArticleId IdType="pmc">PMC9888384</ArticleId><ArticleId IdType="pubmed">36719370</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Human autoantibodies neutralizing type I IFNs: From 1981 to 2023. Immunol. Rev. 322, 98–112 (2024), 10.1111/imr.13304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13304</ArticleId><ArticleId IdType="pmc">PMC10950543</ArticleId><ArticleId IdType="pubmed">38193358</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale B. G., Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. Eur. J. Immunol. 53, 2250164 (2023), 10.1002/eji.202250164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202250164</ArticleId><ArticleId IdType="pubmed">37027328</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathian A., et al. , Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. Ann. Rheum. Dis. 81, 1695–1703 (2022), 10.1136/ard-2022-222549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222549</ArticleId><ArticleId IdType="pubmed">35973806</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto A. M., et al. , Association of endogenous anti–interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 2407–2415 (2011), 10.1002/art.30399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30399</ArticleId><ArticleId IdType="pmc">PMC4028124</ArticleId><ArticleId IdType="pubmed">21506093</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccuti G., et al. , A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy, Italy: Letter to the editor. J. Endocrinol. Invest. 43, 1175–1177 (2020), 10.1007/s40618-020-01323-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01323-4</ArticleId><ArticleId IdType="pmc">PMC7282538</ArticleId><ArticleId IdType="pubmed">32519200</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisel C., et al. , Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J. Clin. Invest. 131, e150867 (2021), 10.1172/JCI150867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150867</ArticleId><ArticleId IdType="pmc">PMC8279584</ArticleId><ArticleId IdType="pubmed">34061776</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021), 10.1084/jem.20210554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20210554</ArticleId><ArticleId IdType="pmc">PMC8077172</ArticleId><ArticleId IdType="pubmed">33890986</ArticleId></ArticleIdList></Reference><Reference><Citation>Casanova J. L., Abel L., Mechanisms of viral inflammation and disease in humans. Science 374, 1080–1086 (2021), 10.1126/science.abj7965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abj7965</ArticleId><ArticleId IdType="pmc">PMC8697421</ArticleId><ArticleId IdType="pubmed">34822298</ArticleId></ArticleIdList></Reference><Reference><Citation>Manry J., et al. , The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc. Natl. Acad. Sci. U.S.A. 119, e2200413119 (2022), 10.1073/pnas.2200413119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2200413119</ArticleId><ArticleId IdType="pmc">PMC9173764</ArticleId><ArticleId IdType="pubmed">35576468</ArticleId></ArticleIdList></Reference><Reference><Citation>Abers M. S., et al. , Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 99, 917–921 (2021), 10.1111/imcb.12495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imcb.12495</ArticleId><ArticleId IdType="pmc">PMC8444766</ArticleId><ArticleId IdType="pubmed">34309902</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y., et al. , COVID-19 convalescent plasma composition and immunological effects in severe patients. J. Autoimmun. 118, 102598 (2021), 10.1016/j.jaut.2021.102598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102598</ArticleId><ArticleId IdType="pmc">PMC7826092</ArticleId><ArticleId IdType="pubmed">33524876</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S. E., et al. , New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021), 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauvineau-Grenier A., et al. , Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital. J. Clin. Immunol. 43, 459–470 (2022), 10.21203/rs.3.rs-915062/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-915062/v1</ArticleId><ArticleId IdType="pmc">PMC8791677</ArticleId><ArticleId IdType="pubmed">35083626</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalves D., et al. , Antibodies against type I interferon: Detection and association with severe clinical outcome in COVID-19 patients. Clin. Transl. Immunol. 10, e1327 (2021), 10.1002/cti2.1327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1327</ArticleId><ArticleId IdType="pmc">PMC8370568</ArticleId><ArticleId IdType="pubmed">34429968</ArticleId></ArticleIdList></Reference><Reference><Citation>Koning R., et al. , Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021), 10.1007/s00134-021-06392-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06392-4</ArticleId><ArticleId IdType="pmc">PMC8034036</ArticleId><ArticleId IdType="pubmed">33835207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemarquis A., et al. , Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. J. Allergy Clin. Immunol. 148, 96–98 (2021), 10.1016/j.jaci.2021.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.03.034</ArticleId><ArticleId IdType="pmc">PMC8051851</ArticleId><ArticleId IdType="pubmed">33892926</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanich X., et al. , Pre-existing autoantibodies neutralizing high concentrations of type I interferons in almost 10% of COVID-19 patients admitted to intensive care in Barcelona. J. Clin. Immunol. 41, 1733–1744 (2021), 10.1007/s10875-021-01136-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01136-x</ArticleId><ArticleId IdType="pmc">PMC8475877</ArticleId><ArticleId IdType="pubmed">34570326</ArticleId></ArticleIdList></Reference><Reference><Citation>Troya J., et al. , Neutralizing autoantibodies to Type I IFNs in &gt;10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021), 10.1007/s10875-021-01036-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01036-0</ArticleId><ArticleId IdType="pmc">PMC8043439</ArticleId><ArticleId IdType="pubmed">33851338</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst M. G. P., et al. , Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021), 10.1126/scitranslmed.abh2624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abh2624</ArticleId><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez S. E., et al. , Neutralizing autoantibodies to Type I interferons in COVID-19 convalescent donor plasma. J. Clin. Immunol. 41, 1169–1171 (2021), 10.1007/s10875-021-01060-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01060-0</ArticleId><ArticleId IdType="pmc">PMC8132742</ArticleId><ArticleId IdType="pubmed">34009544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang E. Y., et al. , Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021), 10.1038/s41586-021-03631-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler C. G. K., et al. , Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19. Cell 184, 4713–4733.e4722 (2021), 10.1016/j.cell.2021.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.07.023</ArticleId><ArticleId IdType="pmc">PMC8299217</ArticleId><ArticleId IdType="pubmed">34352228</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbil B., et al. , Early and rapid identification of COVID-19 patients with neutralizing type I interferon auto-antibodies. J. Clin. Immunol. 42, 1111–1129 (2022), 10.1007/s10875-022-01252-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01252-2</ArticleId><ArticleId IdType="pmc">PMC9069123</ArticleId><ArticleId IdType="pubmed">35511314</ArticleId></ArticleIdList></Reference><Reference><Citation>Carapito R., et al. , Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. Sci. Transl. Med. 14, eabj7521 (2022), 10.1126/scitranslmed.abj7521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abj7521</ArticleId><ArticleId IdType="pubmed">34698500</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasca F., et al. , Anti-IFN-alpha/-omega neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and laboratory biomarkers of disease severity. Eur. J. Immunol. 52, 1120–1128 (2022), 10.1002/eji.202249824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202249824</ArticleId><ArticleId IdType="pmc">PMC9087404</ArticleId><ArticleId IdType="pubmed">35419822</ArticleId></ArticleIdList></Reference><Reference><Citation>Raadsen M. P., et al. , Interferon-alpha2 auto-antibodies in convalescent plasma therapy for COVID-19. J. Clin. Immunol. 42, 232–239 (2022), 10.1007/s10875-021-01168-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01168-3</ArticleId><ArticleId IdType="pmc">PMC8586830</ArticleId><ArticleId IdType="pubmed">34767118</ArticleId></ArticleIdList></Reference><Reference><Citation>Simula E. R., et al. , Increased presence of antibodies against type I interferons and human endogenous retrovirus W in intensive care unit COVID-19 patients. Microbiol. Spectr 10, e0128022 (2022), 10.1128/spectrum.01280-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.01280-22</ArticleId><ArticleId IdType="pmc">PMC9430400</ArticleId><ArticleId IdType="pubmed">35852349</ArticleId></ArticleIdList></Reference><Reference><Citation>Soltani-Zangbar M. S., et al. , A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients. Cell Commun. Signal. 20, 106 (2022), 10.1186/s12964-022-00903-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12964-022-00903-6</ArticleId><ArticleId IdType="pmc">PMC9287826</ArticleId><ArticleId IdType="pubmed">35842705</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamacchia G., et al. , Clinical and immunological features of SARS-CoV-2 breakthrough infections in vaccinated individuals requiring hospitalization. J. Clin. Immunol. 42, 1379–1391 (2022), 10.1007/s10875-022-01325-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01325-2</ArticleId><ArticleId IdType="pmc">PMC9674730</ArticleId><ArticleId IdType="pubmed">35809212</ArticleId></ArticleIdList></Reference><Reference><Citation>Busnadiego I., et al. , Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease. PLoS Biol. 20, e3001709 (2022), 10.1371/journal.pbio.3001709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001709</ArticleId><ArticleId IdType="pmc">PMC9286229</ArticleId><ArticleId IdType="pubmed">35788562</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto S., et al. , Neutralizing type I interferon autoantibodies in Japanese patients with severe COVID-19. J. Clin. Immunol. 42, 1360–1370 (2022), 10.1007/s10875-022-01308-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01308-3</ArticleId><ArticleId IdType="pmc">PMC9243824</ArticleId><ArticleId IdType="pubmed">35764767</ArticleId></ArticleIdList></Reference><Reference><Citation>Savvateeva E., et al. , Microarray-based detection of antibodies against SARS-CoV-2 proteins, common respiratory viruses and type I interferons. Viruses 13, 2553 (2021), 10.3390/v13122553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13122553</ArticleId><ArticleId IdType="pmc">PMC8705234</ArticleId><ArticleId IdType="pubmed">34960822</ArticleId></ArticleIdList></Reference><Reference><Citation>Credle J. J., et al. , Unbiased discovery of autoantibodies associated with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat. Biomed. Eng. 6, 992–1003 (2022), 10.1038/s41551-022-00925-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41551-022-00925-y</ArticleId><ArticleId IdType="pmc">PMC10034860</ArticleId><ArticleId IdType="pubmed">35986181</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrikov S. S., et al. , Anti-interferon alpha autoantibodies and their significance in COVID-19. Russ. J. Infect. Immun. 12, 279–287 (2022), 10.15789/2220-7619-aaa-1789.</Citation><ArticleIdList><ArticleId IdType="doi">10.15789/2220-7619-aaa-1789</ArticleId></ArticleIdList></Reference><Reference><Citation>Schidlowski L., Iwamura A. P. D., Covid S. U. D., Condino-Neto A., Prando C., Diagnosis of APS-1 in two siblings following life-threatening COVID-19 pneumonia. J. Clin. Immunol. 42, 749–752 (2022), 10.1007/s10875-022-01245-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01245-1</ArticleId><ArticleId IdType="pmc">PMC8933185</ArticleId><ArticleId IdType="pubmed">35305203</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrestier R., et al. , Auto-antibodies against type I IFNs in &gt; 10% of critically ill COVID-19 patients: A prospective multicentre study. Ann. Intensive Care 12, 121 (2022), 10.1186/s13613-022-01095-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-022-01095-5</ArticleId><ArticleId IdType="pmc">PMC9803887</ArticleId><ArticleId IdType="pubmed">36586050</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm L., et al. , Immune dysregulation in acute SARS-CoV-2 infection. Pathog. Immun. 7, 143–170 (2022), 10.20411/pai.v7i2.537.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v7i2.537</ArticleId><ArticleId IdType="pmc">PMC9973727</ArticleId><ArticleId IdType="pubmed">36865568</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippot Q., et al. , Autoantibodies neutralizing type I IFNs in the bronchoalveolar lavage of at least 10% of patients during life-threatening COVID-19 pneumonia. J. Clin. Immunol. 43, 1093–1103 (2023), 10.1007/s10875-023-01512-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-023-01512-9</ArticleId><ArticleId IdType="pmc">PMC10199445</ArticleId><ArticleId IdType="pubmed">37209324</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanker M., et al. , Autoantibodies neutralizing Type III interferons are uncommon in patients with severe coronavirus disease 2019 pneumonia. J. Interferon Cytokine Res. 43, 379–393 (2023), 10.1089/jir.2023.0003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2023.0003</ArticleId><ArticleId IdType="pmc">PMC10517334</ArticleId><ArticleId IdType="pubmed">37253131</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen K. S., et al. , Examination of autoantibodies to type I interferon in patients suffering from long COVID. J. Med. Virol. 95, e29089 (2023), 10.1002/jmv.29089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29089</ArticleId><ArticleId IdType="pubmed">37698062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons M. J., Mayanga-Herrera A., Palomino-Kobayashi L. A., Quispe A. M., Ugarte-Gil M. F., High anti-interferon-alpha autoantibody levels in severe/critical COVID-19 patients from Peru. J. Interferon Cytokine Res. 43, 565–570 (2023), 10.1089/jir.2023.0087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2023.0087</ArticleId><ArticleId IdType="pubmed">37906115</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., et al. , Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881–895.e820 (2022), 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., et al. , Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. 219, e20220514 (2022), 10.1084/jem.20220514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220514</ArticleId><ArticleId IdType="pmc">PMC9485705</ArticleId><ArticleId IdType="pubmed">36112363</ArticleId></ArticleIdList></Reference><Reference><Citation>Alotaibi F., et al. , Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE clinical trial. Influenza Other Respir. Viruses 17, e13116 (2023), 10.1111/irv.13116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13116</ArticleId><ArticleId IdType="pmc">PMC10028524</ArticleId><ArticleId IdType="pubmed">36960162</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Hir A., et al. , Yellow fever vaccine-associated neurologic and viscerotropic disease: A 10-year case series of the French National Reference Center for arboviruses with clinical and immunological insights. J. Travel Med. 31, taad160 (2023), 10.1093/jtm/taad160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jtm/taad160</ArticleId><ArticleId IdType="pubmed">38123499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486 (2021), 10.1084/jem.20202486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202486</ArticleId><ArticleId IdType="pmc">PMC7871457</ArticleId><ArticleId IdType="pubmed">33544838</ArticleId></ArticleIdList></Reference><Reference><Citation>Gervais A., et al. , Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. J. Exp. Med. 220, e20230661 (2023), 10.1084/jem.20230661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20230661</ArticleId><ArticleId IdType="pmc">PMC10287549</ArticleId><ArticleId IdType="pubmed">37347462</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw E. R., Rosen L. B., Ding L., Holland S. M., Su H. C., Detection of neutralizing anti-type 1 interferon autoantibodies. Curr. Protoc 2, e511 (2022), 10.1002/cpz1.511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpz1.511</ArticleId><ArticleId IdType="pmc">PMC9389601</ArticleId><ArticleId IdType="pubmed">35976040</ArticleId></ArticleIdList></Reference><Reference><Citation>Peel J. N., et al. , Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals. J. Clin. Invest. 134, e178263 (2024), 10.1172/JCI178263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI178263</ArticleId><ArticleId IdType="pmc">PMC11014650</ArticleId><ArticleId IdType="pubmed">38470480</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih H.-P., et al. , Pathogenic autoantibodies to IFN-γ act through the impedance of receptor assembly and Fc-mediated response. J. Exp. Med. 219, e20212126 (2022), 10.1084/jem.20212126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20212126</ArticleId><ArticleId IdType="pmc">PMC9287643</ArticleId><ArticleId IdType="pubmed">35833912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., et al. , mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Immunity 54, 2893–2907.e2895 (2021), 10.1016/j.immuni.2021.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8452492</ArticleId><ArticleId IdType="pubmed">34614412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A., et al. , Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201–1213.e1214 (2021), 10.1016/j.cell.2021.01.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.050</ArticleId><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann H. H., Schneider W. M., Rice C. M., Interferons and viruses: An evolutionary arms race of molecular interactions. Trends Immunol. 36, 124–138 (2015), 10.1016/j.it.2015.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.01.004</ArticleId><ArticleId IdType="pmc">PMC4384471</ArticleId><ArticleId IdType="pubmed">25704559</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFleur D. W., et al. , Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J. Biol. Chem. 276, 39765–39771 (2001), 10.1074/jbc.M102502200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M102502200</ArticleId><ArticleId IdType="pubmed">11514542</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks Z. R. C., et al. , Properties and functions of the novel type I interferon epsilon. Semin. Immunol. 43, 101328 (2019), 10.1016/j.smim.2019.101328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2019.101328</ArticleId><ArticleId IdType="pubmed">31734130</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris B. D., Schreiter J., Chevrier M., Jordan J. L., Walter M. R., Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R. J. Biol. Chem. 293, 16057–16068 (2018), 10.1074/jbc.RA118.003617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.003617</ArticleId><ArticleId IdType="pmc">PMC6187621</ArticleId><ArticleId IdType="pubmed">30171073</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufour J. H., et al. , IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168, 3195–3204 (2002), 10.4049/jimmunol.168.7.3195.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3195</ArticleId><ArticleId IdType="pubmed">11907072</ArticleId></ArticleIdList></Reference><Reference><Citation>Abolhassani H., et al. , Inherited IFNAR1 deficiency in a child with both critical COVID-19 pneumonia and multisystem inflammatory syndrome. J. Clin. Immunol. 42, 471–483 (2022), 10.1007/s10875-022-01215-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-022-01215-7</ArticleId><ArticleId IdType="pmc">PMC8798309</ArticleId><ArticleId IdType="pubmed">35091979</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J. Exp. Med. 219, e20220028 (2022), 10.1084/jem.20220028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220028</ArticleId><ArticleId IdType="pmc">PMC9026234</ArticleId><ArticleId IdType="pubmed">35442418</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Herpes simplex encephalitis in a patient with a distinctive form of inherited IFNAR1 deficiency. J. Clin. Invest. 131, e139980 (2020), 10.1172/JCI139980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139980</ArticleId><ArticleId IdType="pmc">PMC7773360</ArticleId><ArticleId IdType="pubmed">32960813</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez N., et al. , Inherited IFNAR1 deficiency in otherwise healthy patients with adverse reaction to measles and yellow fever live vaccines. J. Exp. Med. 216, 2057–2070 (2019), 10.1084/jem.20182295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20182295</ArticleId><ArticleId IdType="pmc">PMC6719432</ArticleId><ArticleId IdType="pubmed">31270247</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C. J. A., et al. , Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci. Transl. Med. 7, 307ra154 (2015), 10.1126/scitranslmed.aac4227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac4227</ArticleId><ArticleId IdType="pmc">PMC4926955</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C. J. A., et al. , Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic. J. Exp. Med. 219, e20212427 (2022), 10.1084/jem.20212427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20212427</ArticleId><ArticleId IdType="pmc">PMC9026249</ArticleId><ArticleId IdType="pubmed">35442417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreins A. Y., et al. , Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212, 1641–1662 (2015), 10.1084/jem.20140280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20140280</ArticleId><ArticleId IdType="pmc">PMC4577846</ArticleId><ArticleId IdType="pubmed">26304966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv G., et al. , Novel mutations of TYK2 leading to divergent clinical phenotypes. Pediatr. Allergy Immunol. 33, e13671 (2022), 10.1111/pai.13671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13671</ArticleId><ArticleId IdType="pubmed">34569645</ArticleId></ArticleIdList></Reference><Reference><Citation>Minegishi Y., et al. , Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25, 745–755 (2006), 10.1016/j.immuni.2006.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2006.09.009</ArticleId><ArticleId IdType="pubmed">17088085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez N., et al. , Life-threatening influenza pneumonitis in a child with inherited IRF9 deficiency. J. Exp. Med. 215, 2567–2585 (2018), 10.1084/jem.20180628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180628</ArticleId><ArticleId IdType="pmc">PMC6170168</ArticleId><ArticleId IdType="pubmed">30143481</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan C. J., et al. , Human IFNAR2 deficiency: Lessons for antiviral immunity. Sci. Transl. Med. 7, 307ra154 (2015), 10.1126/scitranslmed.aac4227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aac4227</ArticleId><ArticleId IdType="pmc">PMC4926955</ArticleId><ArticleId IdType="pubmed">26424569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufour J. H., et al. , IFN-γ-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking1. J. Immunol. 168, 3195–3204 (2002), 10.4049/jimmunol.168.7.3195.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3195</ArticleId><ArticleId IdType="pubmed">11907072</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiguro N., et al. , Induction of interferon-inducible protein-10 and monokine induced by interferon-gamma from human endothelial cells infected with Influenza A virus. Arch. Virol. 149, 17–34 (2003), 10.1007/s00705-003-0208-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-003-0208-4</ArticleId><ArticleId IdType="pubmed">14689273</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell J., et al. , Direct, Interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during Hepatitis C virus infection. J. Virol. 88, 1582–1590 (2014), 10.1128/jvi.02007-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02007-13</ArticleId><ArticleId IdType="pmc">PMC3911583</ArticleId><ArticleId IdType="pubmed">24257594</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauty A., et al. , The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells1. J. Immunol. 162, 3549–3558 (1999), 10.4049/jimmunol.162.6.3549.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.162.6.3549</ArticleId><ArticleId IdType="pubmed">10092813</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Greater risk of COVID-19 pneumonia in children with autoantibodies neutralizing IFN-a than in those with autoantibodies neutralizing IFN-w. J. Exp. Med. 221, e20231353 (2023), 10.1084/jem.20231353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20231353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., et al. , Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. Sci. Immunol. 8, eabp8966 (2022), 10.1126/sciimmunol.abp8966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abp8966</ArticleId><ArticleId IdType="pmc">PMC9210448</ArticleId><ArticleId IdType="pubmed">35857576</ArticleId></ArticleIdList></Reference><Reference><Citation>Love M. I., Huber W., Anders S., Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Korsunsky I., et al. , Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6884693</ArticleId><ArticleId IdType="pubmed">31740819</ArticleId></ArticleIdList></Reference><Reference><Citation>Aran D., et al. , Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340744</ArticleId><ArticleId IdType="pubmed">30643263</ArticleId></ArticleIdList></Reference><Reference><Citation>Monaco G., et al. , RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. Cell Rep. 26, 1627–1640.e7 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367568</ArticleId><ArticleId IdType="pubmed">30726743</ArticleId></ArticleIdList></Reference><Reference><Citation>Blighe K., Rana S. S, Lewis M.
M, EnhancedVolcano: Publication-ready volcano plots with enhanced colouring and labeling (R package version 1120, 2021). https://rdrr.io/bioc/EnhancedVolcano/. Accessed 1 July 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>